Figure 5
Effect of valproate (VA) on glutamate (Glu)-induced COX-2 and P-gp activity: (a) Cells in different wells were treated 50 µM glutamate, 600 µM VA, 2 µM CCX or their combination. In combinational treatments, cells were exposed to VA for 2 h and CCX for 30 min prior to treatment with 50 µM glutamate for further 12 h. After treatment, cells were harvested to assess COX-2 activity. (b) Cells in different wells were treated 50 µM glutamate, 300–600 µM VA, 2 µM CCX, 50 µM VPL or their combination. After treatment, P-gp activity was measured on live cells by rhodamine 123 efflux assay. (c) P-gp specific ATPase assay with increasing concentration of VA. Data were represented in mean ± S.D. of at least four independent experiments (three in case of Fig. 5c). (*p < 0.05, **p < 0.01, compared to VC/baseline; #p < 0.05, ##p < 0.01, compared to glutamate-treated group).
